During the past decade, Gyeonggi-Do Clinical Site3 conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gyeonggi-Do Clinical Site3" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Gyeonggi-Do Clinical Site3" are "Gastric Cancer" (2 trials). Many other conditions were trialed in "Gyeonggi-Do Clinical Site3" in a lesser frequency.

Most popular intervention types in "Gyeonggi-Do Clinical Site3" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Capecitabine" (2 trials), "Oxaliplatin" (2 trials), "Placebo" (2 trials), "Nivolumab" (1 trials) and "ONO-4538" (1 trials). Other intervention names were less common.

The vast majority of trials in "Gyeonggi-Do Clinical Site3" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Gyeonggi-Do Clinical Site3". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Gyeonggi-Do Clinical Site3, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Gyeonggi-Do Clinical Site3, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".